FULC - Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc Logo

FULC - Fulcrum Therapeutics Inc

https://www.fulcrumtx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bearish
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Avis Budget Gr ( NASDAQ:CAR ) , Cardiff Oncology ( NASDAQ:CRDF )
Benzinga • 1 month, 2 weeks ago • score: -0.36
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of Avis Budget Group, Inc. CAR fell sharply in pre-market trading after the company reported second-quarter financial results.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined diseases in areas of high unmet medical need in the United States. The company is headquartered in Cambridge, Massachusetts.

52W High
$9.30
52W Low
$2.32
MA Status:
50D: Below 200D: Above
Beta (~1 neutral, <0.9 lower risk)
2.81
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-3.10
EV/Revenue (<3 favorable)
117.40
P/S (TTM) (<3 favorable)
5.12
P/B (<3 favorable)
1.93
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
1.82%
Institutions (25–75% balanced)
101.55%
Shares Outstanding
54,092,000
Float
23,764,100
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
-52,743,000
EPS (TTM)
-1.18
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.30%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Bearish momentum
Value
0.0761
Previous
0.0783
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025